2 recruiting, 1 terminated, 1 unknown, 1 withdrawn. 2 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Withdrawn 1 |
| Not applicable | 1 | Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Tumor Skin: new trials by email Literature Review of Tumor Skin trials Research Report on Tumor Skin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of OBX-115 in Advanced Solid Tumors OBX-115 - Tumor Skin, Metastatic Melanoma | Phase 1 / Phase 2 | Recruiting | Obsidian Therapeutics, Inc. | 254 | 2023-10-25 | 2026-10-05 |
| Microscopy Imaging of Whole-mount Stained Human Tissues Tumor, Brain, Tumor, Breast | Unknown | National Taiwan University Hospital | 250 | 2023-01-10 | 2024-08-21 | |
| Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma Melanoma, Immune Defect | Recruiting | Institut Claudius Regaud | 100 | 2023-01-01 | 2025-05-29 | |
| Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry Oxygen - Skin Lesion, Skin Cancer | Not applicable | Terminated | West Virginia University | 3 | 2019-10-17 | 2026-02-27 |
| Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma Talimogene laherparepvec (T-Vec), Dabrafenib (BRAF Inhibitor), Trametinib (MEK Inhibitor) - Melanoma (Skin), Melanoma Stage IIIb-IVM1a | Phase 2 | Withdrawn | TriHealth Inc. | 2019-06-24 | 2020-10-19 |
Skin Neoplasms (5) · Melanoma (4) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1)
Neoplasms (5) · Neoplasms by Site (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Neoplasms by Histologic Type (4) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Nerve Tissue (4) · Neuroectodermal Tumors (4) · Neuroendocrine Tumors (4) · Nevi and Melanomas (4) · Brain Diseases (1) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Central Nervous System Diseases (1)
Oxygen (1) · dabrafenib (1) · talimogene laherparepvec (1) · trametinib (1)
Institut Claudius Regaud (1) · National Taiwan University Hospital (1) · Obsidian Therapeutics, Inc. (1) · TriHealth Inc. (1) · West Virginia University (1)
United States (3) · Australia (1) · France (1) · Taiwan (1)